However, with the development of novel therapeutic modalities, including advanced ADCs, bispecific antibodies, immune checkpoint inhibitors, CAR-T cells, and liquid biopsy, the treatment landscape for HER2-positive GC is poised for transformative advancements. The gene discussed is ERBB2; the disease is gastric cancer.